Results 241 to 250 of about 549,379 (280)

Publication Only

HemaSphere, Volume 9, Issue S1, June 2025.
wiley   +1 more source

Masthead: (View 3/2025)

VIEW, Volume 6, Issue 3, June 2025.
wiley   +1 more source

Some of the next articles are maybe not open access.

Related searches:

X-ray-responsive polypeptide nanogel for concurrent chemoradiotherapy

Journal of Controlled Release, 2021
Concurrent chemoradiotherapy (CCRT) is a standard treatment regimen for medically inoperable stage III non-small-cell lung carcinoma (NSCLC) owing to its superior prognostics compared with the sequential modality. Nevertheless, the current pattern of CCRT still fails to provide satisfactory survival outcome. Furthermore, CCRT is always accompanied by a
Weiguo Xu, Baosheng Li, Heng-Wei Xu, Ning Zhang, Xuesi Chen, Changsheng Yang, Juan Wang, Jianxun Ding, Z. Wang   +8 more
openaire   +4 more sources

Efficacy and safety of thalidomide in preventing oral mucositis in patients with nasopharyngeal carcinoma undergoing concurrent chemoradiotherapy: A multicenter, open‐label, randomized controlled trial

Cancer, 2021
This multicenter clinical trial was designed to evaluate the efficacy and safety of thalidomide (THD) in preventing oral mucositis (OM) in patients with nasopharyngeal carcinoma (NPC) undergoing concurrent chemoradiotherapy (CCRT).
Leifeng Liang, Zhi-bing Liu, Haisheng Zhu, Hongqian Wang, Yan-sheng Wei, X. Ning, Zhiling Shi, Liujun Jiang, Zhan Lin, Haolin Yan, Rensheng Wang, Kai Hu   +11 more
semanticscholar   +1 more source

A randomized phase III trial of adjuvant chemotherapy versus concurrent chemoradiotherapy for postoperative cervical cancer: Japanese Gynecologic Oncology Group study (JGOG1082)

International Journal of Gynecological Cancer, 2021
Background The standard treatment for stage IB–IIB cervical cancer is radiotherapy or radical hysterectomy; after radical hysterectomy, adjuvant concurrent chemoradiotherapy is recommended for patients with high risk factors. However, adjuvant concurrent
A. Furusawa, M. Takekuma, K. Mori, T. Usami, E. Kondo, S. Nishio, K. Nishino, Y. Miyamoto, R. Yoshimura, Miho Watanabe, M. Mikami, T. Enomoto   +11 more
semanticscholar   +1 more source

Adjuvant concurrent chemoradiotherapy in extrahepatic cholangiocarcinoma.

Journal of Clinical Oncology, 2020
4583 Background: Resected cholangiocarcinomas are rare and have high relapse rates. Adjuvant chemotherapy is the standard of care (BiLCAP Trial). Adjuvant radiation therapy benefit is not well defined. This study aims to evaluate survival outcomes of the effect of adjuvant chemoradiotherapy compared to chemotherapy in extrahepatic cholangiocarcinoma (
Feng Tian, Mehmet Akce, Walid L. Shaib, Pretesh Patel, J.Y. Lin, Bassel F. El-Rayes, Zhengjia Chen, Christina Wu, Katerina Mary Zakka, Olatunji B. Alese   +9 more
openaire   +2 more sources

Concurrent chemoradiotherapy for head and neck cancer

Seminars in Oncology, 2004
Concurrent chemoradiotherapy (CRT) has been shown to be superior to radiotherapy (RT) alone in several clinical therapeutic settings for head and neck cancer (HNC). In unresectable disease, CRT is superior to RT alone, and for resectable advanced disease, it may serve as a substitute for initial surgery, with planned salvage surgery as a backup. In the
Everett E. Vokes, Bruce Brockstein
openaire   +3 more sources

Induction Chemotherapy plus Concurrent Chemoradiotherapy vs Concurrent Chemoradiotherapy in Elderly Patients with Advanced Nasopharyngeal Carcinoma

Otolaryngology–Head and Neck Surgery, 2017
ObjectiveThis study aimed to compare survival and toxicity between induction chemotherapy followed by concurrent chemoradiotherapy (IC + CCRT) and concurrent chemoradiotherapy (CCRT) alone in elderly patients with advanced nasopharyngeal carcinoma (NPC).Study DesignPropensity‐matched analysis of survival and toxicity in a retrospective elderly cohort ...
Jiaojian Wang, Yanhua Xu, Yanhua Xu, Jian Song, Chunlin Wang, Xi Tang, Xi Tang   +6 more
openaire   +3 more sources

Concurrent chemoradiotherapy in locoregionally recurrent nasopharyngeal carcinoma

International Journal of Radiation Oncology*Biology*Physics, 2004
To analyze the results of concurrent chemoradiotherapy in patients with locoregional recurrent nasopharyngeal carcinoma.We performed a retrospective analysis of 35 patients with locoregional recurrent nasopharyngeal carcinoma referred to our department between March 1994 and November 2002.
Swan-Swan Leong, Joseph Wee, Donald Poon, Zee Wan Wong, Eng Huat Tan, Terence Tan, Yin Bun Cheung, Eu-Tiong Chua, Kam Weng Fong, Swee-Peng Yap   +9 more
openaire   +3 more sources

A critical overview of concurrent chemoradiotherapy in cervical cancer

Current Oncology Reports, 2004
In February 1999, the National Cancer Institute of the US National Institutes of Health issued a communication stating that concurrent chemoradiotherapy should be considered as standard treatment for cervical cancer. This statement was based on the publication of five randomized prospective trials.
Juan J. Sardi, Juan E. Sardi, María A. Boixadera   +2 more
openaire   +3 more sources